NASDAQHealth CareMedical DevicesSnapshot 2026-07-23
Reading APYX? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround story with a focus on growth and operational improvement. The current thesis state is intact, with management prioritizing revenue growth and cash flow despite recent volatility in financial performance.
The market seems to have priced in a justified valuation, with low fragility and an expectations gap indicating that investors are not overly optimistic. APYX trades at a premium compared to its peers, suggesting that some growth potential is already reflected in its valuation.
Fundamentals are likely to show continued volatility in revenue and operating income. Management is on track with revenue guidance but has struggled to maintain consistent profitability and positive cash flow.
The long-term thesis hinges on the performance of sector bellwethers like ABT, SYK, and MDT, as their results could significantly impact APYX. Additionally, any changes in guidance from APYX could affect investor confidence.
Over the next 1 to 3 years, APYX's success will depend on its ability to stabilize revenue and improve cash flow while navigating sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Company momentum fell by 37.2 points (from 100.0 to 62.8).
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings results will show if the company can meet or exceed expectations. This impacts investor sentiment.
Confirms one read:Q2 earnings are much better than analyst expectations.
Confirms the other:Q2 earnings fall short of analyst expectations.
Why it matters: The earnings report will provide updates on revenue, cash flow, and operating income. It is a key moment for investors.
Confirms one read:Earnings report shows revenue growth and positive cash flow.
Confirms the other:Earnings report shows declining revenue and negative cash flow.
Why it matters: Updates from the new Executive Chairman could signal changes in strategy or direction. This could impact future growth.
Confirms one read:The company shares new plans led by the Executive Chairman.
Confirms the other:No new plans are shared after the appointment.
Why it matters: Better operating income shows the company is managing costs well. This can help investor trust.
Confirms:Operating income turns positive or gets better from -$911,000 in Q1 2026.
Disproves:Operating income stays negative or gets worse in Q2 2026.
Why it matters: Positive cash flow from operations is vital for financial health. It shows the company can survive without extra money.
Confirms:Cash from operations turns positive in Q2 2026.
Disproves:Cash from operations remains negative in Q2 2026.
Why it matters: If sector growth speeds up, Apyx could do better. This may improve its outlook.
Confirms:Health Care sector revenue growth exceeds 10% year over year.
Disproves:Sector revenue growth remains below 10% year over year.
Why it matters: An increase in revenue guidance shows management's confidence in growth. It could signal better performance ahead.
Confirms:Management raises total revenue guidance to over $60M for FY2026.
Disproves:Management keeps revenue guidance at or below $59M for FY2026.
